Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01850823 · ClinicalTrials.gov registry record · Phase 3
Clinical Equivalence Study of Mometasone Nasal Spray
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 880
- Enrollment target
NCT01850823 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 880 participants.
The verdict
NCT01850823, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 880 participants
- Enrollment target
Study Summary
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Nasal Spray (Watson Laboratories, Inc) with NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
Interventions
- DRUG placebo
- DRUG Mometasone Nasal Spray
- DRUG Mometasone nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01850823
The ClinicalTrials.gov registry entry for NCT01850823 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 880 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01850823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01850823 about?
NCT01850823 is a clinical study titled "Clinical Equivalence Study of Mometasone Nasal Spray". A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Nasal Spray (Watson Laboratories, Inc) with NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
What is the current status of trial NCT01850823?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2013-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01850823?
The interventions under investigation include: placebo (DRUG), Mometasone Nasal Spray (DRUG), Mometasone nasal spray (DRUG).
Who is sponsoring clinical trial NCT01850823?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.